RAPH.US Raphael Pharmaceutical Inc.

Healthcare Pharmaceuticals USA Stocks
1.51 USD
Close of Oct 17, 2026
0.7480 1.51
Market cap
USD 30.5M
P/E
-
P/B
304.45x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RAPH.US undervalued?

Graham number

The Graham number of Raphael Pharmaceutical Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Raphael Pharmaceutical Inc. fundamental analysis

No fundamental analysis for Raphael Pharmaceutical Inc. yet.

Raphael Pharmaceutical Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.

Full company profile